Harmony Biosciences Holdings, Inc.
HRMY- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001802665
In the last 90 days, Harmony Biosciences Holdings, Inc. insiders filed 0 open-market purchases and 2 sales; 328 institutions reported holding it in 13F filings for Q2 2026, worth $1.97B in total; no superinvestor holds it.
13F holders, Q4 2021
Institutional positions in Harmony Biosciences Holdings, Inc. as of Dec 31, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 147
- +46 vs. Q3 2021
- Shares held
- 44.6M
- +13.6M (+44.1%) vs. Q3 2021
- Total value
- $1.90B
- +$714.5M (+60.3%) vs. Q3 2021
- New holders
- 60
- 40 more added
- Sold out
- 14
- 31 more reduced
1 institution that held it in Q3 2021 haven't filed for Q4 2021 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting HRMY on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 328 | $1.97B |
| Q1 2026 | 311 | $1.57B |
| Q4 2025 | 325 | $1.87B |
| Q3 2025 | 296 | $1.31B |
| Q2 2025 | 279 | $1.62B |
| Q1 2025 | 272 | $1.67B |
| Q4 2024 | 247 | $1.82B |
| Q3 2024 | 234 | $2.01B |
| Q2 2024 | 219 | $1.51B |
| Q1 2024 | 207 | $1.64B |
| Q4 2023 | 221 | $1.54B |
| Q3 2023 | 205 | $1.62B |
| Q2 2023 | 211 | $1.83B |
| Q1 2023 | 218 | $1.68B |
| Q4 2022 | 242 | $2.81B |
| Q3 2022 | 203 | $2.24B |
| Q2 2022 | 184 | $2.34B |
| Q1 2022 | 182 | $2.26B |
| Q4 2021 | 147 | $1.90B |
| Q3 2021 | 102 | $1.19B |
| Q2 2021 | 84 | $790.3M |
| Q1 2021 | 57 | $907.6M |
Institutions, Q4 2021
Shares, value and share of portfolio for each institution holding Harmony Biosciences Holdings, Inc.; share changes are against Q3 2021.